Abstract:Objective. It was to explore the correlation between regulatory T cells (Treg)/T helper cell 17 (Thl7) and the efficacy of receiving a programmed death protein-1 (PD-1) monoclonal antibody (mAb) in patients with advanced non-small-cell lung cancer (NSCLC) complicated with chronic obstructive pulmonary disease (COPD). Methods. The research subjects were 82 patients who were clinically evaluated and treated in the Respiratory Department of Suqian Hospital connected with Xuzhou Medical University from January to December 2021. All of the patients were given PD-1 immunotherapy, and 50 healthy people were chosen as the control group. Classification was carried out according to tumor type and tumor stage. The levels of Th17 and Treg/Th17 in the peripheral blood of patients with different tumor-node-metastasis (TNM) stages and different types were compared, and the immune function, lung function (forced expiratory volume in one second/forced vital capacity (FEV1%/FVC), FEV1%, and FVC), and changes in inflammatory factors were compared before and after treatment. The levels of interleukin (IL)-17, IL-6, tumor necrosis factor (TNF)-α, and transforming growth factor (TGF)-β were compared between the two groups. The correlation between Th17 cells and Treg cells in the peripheral blood of patients with NSCLC complicated with COPD was analyzed. Results. After treatment, the levels of IL-17, IL-6, TNF-α, and TGF-β in patients with NSCLC combined with COPD were notably superior to those in the control group ( P < 0.05 ). The immune function and lung function of the patients were improved after treatment. There were 43 cases of squamous cell carcinoma, 30 cases of adenocarcinoma, and 9 cases of large cell carcinoma. The proportion of Th17 cells to CD4+ T cells in the blood of the three types of patients and the proportion of CD4+CD25HiCD127Lo regulatory T cells to CD4+ lymphocyte cells in Treg cells showed no considerable difference among the different case types ( P > 0.05 ). No considerable difference was indicated in Treg/Th17 in peripheral blood between stage IIIB and stage IV lung cancer patients ( P > 0.05 ). A positive linear correlation was revealed between Th17 cells and Treg cells in the peripheral blood of patients with NSCLC combined with COPD, R = 0.26 , P = 0.039 . Conclusion. Treg and Th17 cells were shown to be much higher in lung cancer patients with COPD, which could lead to immunosuppression and tumor growth. PD-1 therapy for NSCLC has demonstrated efficacy and can improve patients' immunological state while being extremely safe.

Changes of Treg and Th17 Cells in the Peripheral Bloods of Patients with Lung Adenocarcinoma and Their Prognostic Significance

The Changes and Significance of Treg and Th17 in the Peripheral Blood of Patients with Lung Carcinoma

Increased Frequency of Th17 Cells in the Peripheral Blood of Patients with Lung Adenocarcinoma and Its Clinical Significance

IL-17A-producing T Cells Are Associated with the Progression of Lung Adenocarcinoma

Detection of T Lymphocyte Subsets in the Peripheral Blood of Patients with Advanced Lung Adenocarcinoma

P-STAT3 and IL-17 in Tumor Tissues Enhances the Prognostic Value of CEA and CA125 in Patients with Lung Adenocarcinoma

The Changes of Peripheral Blood Lymphocyte Subsets and Cytokine in Patients with Lung Adenocarcinoma at Different Stages

Treg and Th17 Cells in Peripheral Blood of Patients with Non-small Cell Lung Cancer and Their Signification

Detection And Significance Of Tregfoxp3(+) And Th17 Cells In Peripheral Blood Of Non-Small Cell Lung Cancer Patients

Changes of CD4+CD25+CD127-regulatory T Cells Level and Clinical Significance in the Peripheral Blood of Patients with Lung Cancer

Th17 Expression And Il-17 Levels In Laryngeal Squamous Cell Carcinoma Patients

Distribution of Peripheral Blood T Helper 17 Cells and IL-17+FoxP3+T Cells in Patients with Non-Small-cell Lung Cancer

Treg/Th17 imbalance in malignant pleural effusion partially predicts poor prognosis.

RECIPROCAL IMBALANCE OR CO-EXISTENCE? THE DISTRIBUTION OF TH17 AND TREG CELLS IN PERIPHERAL BLOOD LYMPHOCYTES IN PATIENTS WITH NON-SMALL-CELL LUNG CANCER AND ITS SIGNIFICANCE

Lower Expression Level of IL-33 is Associated with Poor Prognosis of Pulmonary Adenocarcinoma.

Expression of Th17 and regulatory T Cells in the Peripheral Blood of Patients with Laryngeal Cancer

Frequency changes in HLA‐I alleles: A marker to guide immunotherapy in lung adenocarcinoma patients and its relationship with tumor mutational burden and PD‐L1 expression

The Detection and Significance of Foxp3+ Regulatory T Cells, Th17 in Peripheral Blood of Non-Small Cell Lung Cancer Patients

Role of T Helper 17 Cytokines in the Tumour Immune Inflammation Response of Patients with Laryngeal Squamous Cell Carcinoma.

Correlation between the Treg/Thl7 Index and the Efficacy of PD-1 Monoclonal Antibody in Patients with Advanced Non-Small-Cell Lung Cancer Complicated with Chronic Obstructive Pulmonary Disease

Prognostic effect of TCF1+ CD8+ T cell and TOX+ CD8+ T cell infiltration in lung adenocarcinoma